BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Japan's Asahi Kasei Corporation (AHKSY.PK) to Buy ZOLL Medical Corporation (ZOLL) for $2.2 Billion


3/12/2012 7:04:33 AM

NEW YORK, March 12, 2012 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, notifies investors of Zoll Medical Corp. (NASDAQ GS:ZOLL) of potential claims of breaches of fiduciary duty and other violations of state law against the board of directors of Zoll in connection with the sale of the company to Asahi Kasei Corporation. It was announced today that Asahi has entered into an agreement to acquire all of the outstanding common stock of Zoll through a cash tender offer for approx. $2.21 billion. Under the terms of the definitive agreement, Asahi intends to commence a tender offer for all of the outstanding shares of common stock of Zoll for $93 per share.

The investigation concerns whether the Zoll Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the company before entering into this transaction and whether Asahi is underpaying for Zoll's shares, thus unlawfully harming stockholders. Indeed, analysts project that the true value of Zoll is at least $100 per share.

If you own Zoll's common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact

Tripp Levy
Tripp Levy PLLC
125 East 82nd Street
9th Floor
New York, New York
Toll Free: 877-772-3975
Email: contact@tripplevy.com

Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE Tripp Levy PLLC



Read at BioSpace.com
Read at Financial Times
Read at Fox News
Read at Boston Globe
Read at Wall Street Journal

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES